Ouro Fino Saúde Animal Participações S.A. (BVMF:OFSA3)
Brazil flag Brazil · Delayed Price · Currency is BRL
26.41
0.00 (0.00%)
At close: Nov 17, 2026
← View all transcripts

Earnings Call: Q3 2026

Nov 13, 2026

Summary

Nine-month revenue exceeded BRL 1 billion, up 26.5%, with growth across production animals, companion animals and international operations. Cash generation remained strong, while management expects a positive Q4 amid delivery and macroeconomic risks.

Marcelo Silva
Financial and Investor Relations Director, Ourofino Saúde Animal Participações

To thank everyone that is here present in our conference about results for the third quarter of 2026. We will be disclosing the results and the performance of the company in the third quarter of this year, and also the nine months of 2026, the main highlights and advances that we had in our business. Alongside me, we have Kleber Gomes, our CEO. He will be giving the initial introduction, discuss a little bit of the business context, the main launches and events that the company has had in this period. After this initial presentation from Kleber, I will be back here to give you more details about the financial performance and the main numbers of the company. Good morning. Kleber, over to you.

Kleber Gomes
CEO, Ourofino Saúde Animal Participações

Hello. Good morning, everyone. It is a pleasure to be here with all of you to give you the initial presentations of the results that we had had of the third quarter of 2026 and the nine months. We can start with a very positive overview, another very strong quarter that we had, amazing growth. Although we have seen some setbacks in the market with the animal health product market, who has had some issues, the high interest rates, the high inflation rates that we have had, the volatility that we also have experienced after the huge election that we have had in Brazil. The market was impacted a little bit with all of that, especially the companion animal market, which was one of the markets that we have seen a bit of a tougher year.

When it comes to production animals, the cattle market continues to be very positive, especially in terms of the pricing, price of the calves. We are very positive right now. On the other hand, we have had some issues with the excess of production. We have had some very positive years, and the producers decide to create more, so we had a surplus of animals, and those are markets that most of the time have been operated with a margin that was negative. However, the portfolio that we have is a protocol portfolios for use, and it has not affected us quite a lot. But in summary, we have a very complicated macroeconomic moment. We have some markets which are a bit more positive, others not so much, but the company overall follows a very strong rhythm, a growth rhythm.

Also, we need to highlight that these reflections that we see right now are at the effect of some of the products that we have launched that I will be talking over. We have launched many other products in 2025 and 2026, which is also a reflection of the beginning of our management. Remember that our production cycle is a bit longer in the sectors, from five to seven years. So we have now been coming to reap some of the benefits that we have started, and the results definitely come in the financial aspect. So we close the nine months with over BRL 1 billion in revenue, a cumulative growth of 26%. We have in the quarter with BRL 429 million of revenue, which is a growth that represents 20.4%, also a very good growth. We are keeping, in a way, all the profitability indicators.

We say that it's always positive and important to grow in revenue, but we also need to grow that maintaining a financial health, giving profitability and taking care of the cash flow always. The accumulated profit, looking at the net income, also grew 26%. Although the quarter grew a bit less, on the quarter, we have had some losses in production. We have talked about this before when we saw a little bit of this reflect here what happened, but after that, we were able to reap some of the adjustments and benefits that we have had, and the results are definitely positive now in face of the issues that we had in the past. We also had in the quarter an investment that was a bit higher in our institutional campaign, our brand campaign, that's called Tá bem cuidado. I'll be talking about more of that later on.

The accumulated, which is how we plan the year, is very well aligned with the growth and the profit. Most important of all is that we're generating a cash that is extremely healthy, robust, that is contributing a lot to the quality of our adjusted EBITDA, despite us not being able to capture a lot in the year. I'm very happy with the overall financial results. All the lines, if we look at the six months results that were disclosed earlier, we were able to gain market share, relevant percentage points. We gained that market share pretty much in all the different lines. Most important of all, if you look, we are in third in rank, competing with companies that are huge, companies that grow even by inorganic movements.

We see that this growth above the market has been extremely positive, and the management that the company is doing is also extremely well aligned. Now, going over to our campaigns, like I said before, I've spoken about this, it's one of the pillars of our strategic planning. We are actually just fulfilling the first year of our strategic plan, which was very aligned with what we planned. We had a session, by the way, with all the leaders and the extended leaders, which are more related to the strategic pillars, precisely to discuss and to summarize all the positive aspects, the aspects that could be improved for the future strategic planning. The overall message says they were extremely well positioned right now. I'll give you an example of our campaigns.

The goal is to make Ourofino, which is already a very loved and well-known company in Brazil, to be even more and grow more along those lines. Our campaign called "Tá bem cuidado" or "You are in good hands" have been growing quite a lot. The goal is to have even more people to have a somewhat new contact with the brand, that can identify with the brand, so we can try to overflow what we are to more people, so those people can consider Ourofino even more as an option to choose from. This is really interesting because our portfolio now has products that are made for retail, for direct selling for retail, for pets, products for the pet, which is very important product. We have done a very specific work with that.

But again, the institutional brand reiterates our strength, and we are very happy with the campaign. We reaped extremely well results from it, and I am sure that will help us even further in the future. When we are talking about brand, it is a constant work. Nothing would be reaped all immediately. Things will take a while to pay back, but of course, I am sure we will get there. And since we are talking about this, another very important pillar is also how we have expanded to the Southern Cone. I even gave some very recent interviews about this, and we are advancing quite well. I think the result this year was also extremely positive. We have Argentina, for example, with a business plan that is very well structured, that had the immersion of our teams there working in Argentina. And we should pretty soon have the first wave of registry, registration submissions.

And like I said, it is a very long-term plan. We most likely will not be able to capture results immediately on that front, but all the actions that need to be done, they are being done, and they are very well structured. The same goes for Uruguay. We have constituted a legal entity in Uruguay. This unit will even be used in order for us to help structure all the payments that we have in this international front, in this expansion, and also to support us with the registration submissions that are going to take place. And in Paraguay, for Paraguay, now it is all about expansion and expanding with our current local partner to increase the geographical expansion and reach with their partner. Things are moving along very well, and it also should have our own team in order to generate demand.

And we even have approved in the last meeting that we had last week, the constitution of the legal entity in Paraguay. So we are moving along. We have very good negotiations with products for Asia that are also moving along. Still very. Haven't been finalized yet. They are still in the paper phase, but they are moving along. And we had other things as well that happened this year. This year, for example, we increased in getting more capacitated and training our commercial team. We had great institutions that supported us in training for the marketing campaigns like ESPM, FIA, which I am sure is going to add many good results in the future.

So the results is there in the numbers, but what makes all of this happen is also all the different actions that we are fulfilling throughout the year that have a very clear direct direction based on our strategic planning. So I am very happy overall. And since we are still talking about products, I also wanted to highlight three new launches, very, very recent for this year. We are bringing Dermotrat Plus, which is an extension of the Dermotrat product that we have had. This is a product that actually complements Dermotrat, the traditional one. This is a spray that is going to be used as an antibacterial for wet injuries. This is better for long animals with low coating because it is a spray, has a better penetration aspect to it. It is a great product. The packaging looks beautiful as well.

It has the safe seal of it that we're trying to get in other products to avoid counterfeit. Dermotrat is one of our champion brands in our companion animals product line, and Dermotrat Plus is here to add to the dermatological products. We also have started an SKU that we wanted to do for quite some time, which is the smaller version of Herbalvet. Herbalvet is the most beloved disinfectant in the market. It's used many different vets and veterinary clinics. People love it. It's one of the most beloved brands, product in the market. We are now getting a smaller version, which is a 400 ml pack size to make it more accessible. We want to make sure that people have better access to purchasing this, and we are now complementing this SKU with the 400 ml pack size version.

Based on the partnership that we have with the STV Argentina company, and we are seeing a partnership that will even have the possibility to expand and to work even more in the future, is that we work with a vaccine called Feedlot Plus for confining, for animals that are confined. It has had great results. Now we're bringing Repromais, which is our vaccine for production animals. Ourofino, by the way, is already one of the market leaders, if not the leader, when it comes to production animals and reproductive animals. We have last year released Sincromais, which is our mineral supplement that helps as well in the reproductive protocols and works alongside those.

We needed a vaccine for that, and there are still many more to come in the reproductive product line so we can more and more consolidate our leadership in this so relevant market, which is a market that has grown quite a lot in the present years with the high calf price has been continued to evolve even more. There's tons of focus here in the production and reproduction lines, product lines for those animals. You can see that we have great releases now in this period that will help us close the year. We definitely have a positive expectation for closing the year. Of course, like I said, it's a difficult period. We have less days to work even because of the cutoff of revenues, and we need to acknowledge only the revenues that were delivered to the clients.

There's also logistic concern because we have seen a little bit of deterioration of our service provider that impacts all the chain. Today, you have a lot of labor competition with different delivery platforms. But we do have a solid plan, the service provider as well, and the idea is that we can have a great fourth quarter to crown the excellent year that we have had of very strong growth, thus restrengthening the position of a extremely important market, which is the health animal product market. I'll go back to Marcelo, and then I'll be later on here to have a Q&A session with all of you. Thank you so much.

Marcelo Silva
Financial and Investor Relations Director, Ourofino Saúde Animal Participações

Thank you so much. I'll be back now to go a bit deeper and into detail for the numbers of the company in the third quarter, starting with the growth. Kleber already talked a little bit about this, and indeed, the company has in its consolidated on nine months a growth of 26.5% when comparing to the same period of the previous year, maintaining a very important growth in the third quarter of 20.4%. This growth comes from the expansion of the product line, but also has a weight and a participation of the different launches that we have had, which makes the reference line becomes more comparable when it comes to the composition of the different products and of the different months of the year. Walking towards a very relevant growth by the end of December of the company overall in all its different business lines.

The growth of revenue is also doing great. We grow 26.5% in net revenue and 26.5% in adjusted net income. This shows the ability of the company to maintain a very good growth level by generating margin and generating cash. The third quarter of 2026, when we compare, we had a higher pressure in the gross profit due to some provisions in stock and higher investment as well in marketing and commercial expenses, which is not going to be a trend for the fourth quarter. However, we still were able to grow to 18.1% in adjusted net income against the revenue. In a way, the growth of margin and revenue in all the different lines, both for the quarter and for the accumulated period of nine months. This is just to give you a graphic overview of the consolidated results of the company by giving the comparison with 2024 even.

You can see that the revenue has grown 20.4% and 51.9% when you are comparing the third quarter of 2024, third quarter of 2025, getting to BRL 429 million in the third quarter of 2026. The gross profit reaches BRL 220.8 million, which is a 51.4% margin. This variation of 51.4% from 52.8% is concentrated in the cattle line, which has had a strong growth, but that line were impacted because of some provisions in the third quarter. However, in a consolidated view, the third quarter had also the impact of a non-recurrent event, but if you get the accumulated in the consolidated view of nine months, we did gain in gross margin, going to 51.4%. If you see that the nine months of 2026, the best gross margin that we have had in the past two years, we went from 50 something 2024 to 51.4% now in 2026.

It shows that in consolidated, the company has been expanding its net revenue, but also expanding its margin. When it comes to production animals, this is the biggest segment that we have in the company that has grown a lot because of new releases, but also in expanding its product line. The growth in the quarter was of 21.1%, a bit beyond the growth of the market for the same period. When you compare with the third quarter, the growth was of 56.4%. You see that we go from a revenue of BRL 210.9 million to BRL 272 million in 2025, capturing the new release of the new products, going toBRL 329.7 million in the third quarter of 2026. The gross profit grew 20%. We went from BRL 107 million, BRL 253 million in the third quarter of 2026. And the consolidated, when you're looking at the nine months, the growth is also very similar.

It went from BRL 419 million in 2024 to BRL 594 million in 2025, up to BRL 758 million now in 2026, by delivering BRL 346 million in gross profit, which is a margin of 45.7%. The line of production animal has three important components. We have the cattle line with an increased margin, the poultry and swine line, which has been growing as well because of the new expansion of vaccination portfolio that we have had. There is also a very important component of partnerships and distribution, like Kleber has just talked about with the partnership with STV Argentina, but we also have other products that since it is relatively slow, lower gross margin, it brought growth and also helped to reducing commercial expenses and also increasing the margin of the company as a whole.

In companion animals, we have had also a strong growth in the third quarter of 13.8% when we compare with the market performance. This market kind of went sideways in 2025 and is keeping the same trend in the first six months of 2026. The growth of the company is beyond the market, mainly because of the new launches of products that we have had that gained space in the market, that had a great adherence by the consumers, like Kleber previously mentioned. It is a segment that has a gross margin around 70%. So we went from 69.6% of gross margin in the third quarter of 2025 to 70%.

The same way that we have looked into the consolidated, we are doing the best relative margin of the units since 2024 by delivering 70.5% of gross margin against what we had had in 2024, and also growing the accumulated of nine months, 26%. So this BU has been growing in the market that has been getting more pressured due to many different factors. There is not one single thing that explains the growth in the pet market. So it is something that the market is also impacted by inflation. It is also connected to the retail market. But anyways, the company has been able to increase and gain market share in the first nine months of the year. On the international operations front, considering that we have subsidiaries in Mexico, Colombia, and other countries, working mainly through our local distribution partners, a strong growth in the third quarter of 23.3%.

The gross margin historically was around 65%, so it is one of the best results that we have had in this business units in terms of profitability. The gross margin the third quarter reached 64% now. You see that the revenue is from BRL 77 million, and we are delivering BRL 113 million in net revenue in our international operations in the 9M with a very positive gross margin. This reflects the execution that we have had of our strategy in broadening and amplifying our expansion in Latin America, especially here in South America, with countries that have a very relevant position in livestock, without even capturing the evolution of the new business that are walking in other countries like Uruguay, Paraguay, and Argentina, like Kleber initially talked about. Now, going over the performance and expenses on the period, we had a small increase of expenses in the third quarter.

The third quarter does carry some important events, like different events, campaigns, commercial campaigns that were necessary in order to increase the sales. The expense that was accumulating 24.2% in the third quarter of 2025 reached 25.1% here in the third quarter of 2026, but keeping the trend of reducing in the 9M because our vision is a period that better reflects the business along the year. The expense that was in 30.5% in 2024 reaches 2026 in the consolidated in 27.9%. We are growing, but also maintaining a constant reduce in the overall SG&A as well. The company maintains the profile in investments. We maintain a continuous agenda in innovation and investigations in innovation and R&D projects, which is the heart of the company, right? Because it gives us the possibility to continue to grow.

The company has investments that sometimes are in more initial stages, which gives more impact within RD&I, which increases expenses, others in the development expenses. In line with this portfolio development, we have more expenses in the allocated R&D because many of the projects, a big number of projects are still in a more initial stage, and that's what keeps and creates the portfolio of a company that wants always to be in the front, the vanguard of innovation, and have high-quality products that are actually making a difference out there in the field. The growth here also represents the growth that we have had in our products, but it's all very circumstantial and depend the way that we build our portfolio as well. In the overall consolidated, we have a very positive performance of our EBITDA.

The EBITDA of the company reached BRL 104 million in the third quarter, a margin that is 24.4%. It's a very important margin. In the consolidated, 20.6%. You see that both the gross profit and the EBITDA in the accumulated in the consolidated nine months shows the trend in growth. This growth is because of the direction of SG&A that I talked before. The composition of the portfolio sometimes might give a margin that is relatively inferior to other periods, but the aggregated volume of added volume, that is the incremental increase in revenue does contribute to the increase of EBITDA and net profit because of those expenses. It's very important that we always proportionally bring results as well.

Going over, now approaching the end, this is what, at the end of the day, corroborates with the strategies that show if the strategies are aligned or not, which is the cash generation of the company. We generated BRL 173 million in operating cash, which shows the growth while maintaining margins, and are always very aware of the working capital of the company so that the use of the cash is adequate, and we continue to grow with the capacity to finance the organic growth with cash that is generated from its own operations. We closed the nine months with BRL 330 million in cash against the BRL 250 million that we had of December of last year, generated BRL 173 million of operating cash. We have also paid some dividends. We considered as well the investments. Remember that this cash generation is already net based on the payment of interest and taxes.

Combining growth and cash generation, that is very relevant in a capital structure that is very comfortable and adequate to our profile of investments. The gross debt of the company has closed the period with BRL 495 million. However, it is substantially made of credit that is towards innovation, Finep, for example, which explains the interest rate of 8.62% per year against an average Selic rate of 13.75%. This is very important because we not only have a debt composition that is quite adequate to our investment profile. When you look at this short and long term, we have 86% of the maturities of this debt. So the aging does fit in our cash flow if you look at the generating cash flow. The nine months is pretty much sufficient for amortization of the main debt on the next two years.

That is what keeps us very confident that we are going to continue to grow with the cash generation and with a very relevant agenda in terms of investment, research, and development, and innovation. This is where I stop the comments that I had regarding some of the results of the third quarter. Now I would like to invite Kleber to come back.

Kleber Gomes
CEO, Ourofino Saúde Animal Participações

Thank you so much, Marcelo. Thank you for the deep dive. I am looking at the screen here just to see the questions that I have had. We do have one question from Gustavo Oba. This is what he says. Well, he is congratulating us for the results, and he is saying that there are two topics that he wishes to approach. First is how the company is looking at the first phase of the tax reform, particularly regarding the end of the monophasic PIS/COFINS tax regime for veterinary medicines.

Are you observing any shifts in customer purchasing behavior or inventory building patterns as we approach the end of the year? Is there any risk of orders being held back or revenue shifting from Q4 2026 to early 2027? The second question relates to inventory provisions and write-offs. Just to confirm my understanding, looking at the cash flow statement, we see an impact from these provisions and write-offs similar to what was recorded in Q2 2026. Is it reasonable to assume that the stabilization of production process continues to negatively impact in Q3 2026 compared to the previous quarter? Well, let me start with the tax reform. Our sector benefits a bit well because we do have some different treatment in terms of the taxes there.

Looking overall aspect, we do not see, looking ahead, many differences to what we have had in terms of the monophasic behavior in the sector here with the new tax reform. So the company overall understands that there will not be big and huge impacts because of that in the tax field. When it comes to the vision that the clients had regarding this, since there will not be big impacts, we understand that the customers as well are not seeing any issue with the purchases now. Of course, sometimes they feel a bit insecure, they have questions regarding this.

Yeah, we, with our internal team and consultants, we have had some lives throughout the past months to give information to those customers in order for them to take and make the best decisions, because sometimes there might even be some gain depending on the situation of the customer by buying with anticipation, anticipated. We are not anticipating any big, huge for the future or for the next quarter when it comes to the new tax reform. When it comes to the provisions, yeah, we had the same issues in the previous quarters because the products were already done, so we had some adjustments. We did it, and like I said in the beginning, my initial comments, we do not see any issues for the future. Quite the opposite, we have had the products resumed, and all the new assessments are coming in great. So zero issues looking ahead.

We have another question here from Joabe. "Good morning, Kleber. Thank you for the opportunity. Congratulations on your work and the results. The question concerns the macroeconomic landscape, which shows a high debt-to-GDP ratio approaching 89%, double-digit interest rates, and an outflow of foreign capital, all of which exert pressure on the exchange rate. How do you view this environment? How might it impact Ourofino's operations, and how are you preparing for such scenario?" I agree with that outlook of the scenario we are seeing that it's a year that demands adjustment in the macroeconomic aspects, but we understand that we're going through a scenario that is very similar to what we had this year. We had this trend of improvement, but things hasn't improved quite like that yet.

We prepared the company for a more adverse scenario, which, from the point of view of management, is being more cautious with investments and how we allocate our capital with expenses without harming the future, without harming our R&D in our commercial areas by always seeking efficiency. And of course, we can profit and leverage a lot of the technology that we have with the new AI technology. For example, we are using more in the company. Almost all the employees have access to some type of AI platform. All the company leadership has access to Claude as well. So I see and I understand that the austerity here and a close management attention to the details, despite growing and despite having the market with positive drives, that we need to have an austerity position as well.

We are preserving cash when it comes to the currency and exchange rate, sorry. We have a balance between purchasing and sales that is quite good. We try not to expose the company a lot, and I pretty much understand that we are preparing within the budget that we are about to finish for 2027 for this. The inflationary pressure is a big deal, however, so we are trying to get the least impact and offsetting as we move along with different opportunities that presents themselves as an efficiency gain. I think that's all the questions we had. Marcelo, do you want to add anything?

Marcelo Silva
Financial and Investor Relations Director, Ourofino Saúde Animal Participações

Just two things here to complement what you said, because our segment, or most of its relevant part, which is the livestock sector, already had quite of a favorable condition when it comes to the new tax reform.

The market already had its base that was favored, and the way that the tax reform is set today does support what we saw before, keeping the benefits by reducing the tax on the chain. It is quite of a neutral effect that we will see with the new tax reform. Since our sector is connected to the production of foods, we see a neutral point in sales. That is why it is not a reason for the customer to stop buying or managing their inventory because of the tax reform. When it comes to expenses and costs, we are definitely looking closely to credit, because we understand that there is a sort of a tax residue in all the different chains and segments that will be further investigated and mitigated based on the way that the tax reform is being drafted.

It is an overall neutral impact for the companies that are part of the agribusiness sector. That is the way we see it. Regarding the macro landscape, without repeating Kleber, specifically due to the concerns in the question, we have a credit condition that does not suffer impact directly from Selic. Our condition is connected to something else, so nothing on the short term. Of course, in the medium to long term, if inflation does not budge and Selic as well does not, this could start influencing the other interest rates. However, non-relevant impact on the short term for the company.

Like also Kleber said, we need to just manage our working capital and our expenses to make sure that we can grow sustainably, and we also see that the crisis might be also an opportunity for those who are well-established and has conditions to grow without assuming too much risk and deteriorate their capital structure.

Kleber Gomes
CEO, Ourofino Saúde Animal Participações

Perfect. Thank you so much. Those are the last questions that we have had. No more questions. I just like to once again thank you all for being here, for attending our live. I just wanted to say that we are overall, again, very happy with the results.

We are optimistic towards the future, but of course, we know about our responsibilities and how much we need to continue to work and continue to have a fair management so that things can continue to go well as the way we are planning and as the way is also stated in our strategic planning. I also like to thank our partners, all our team, because nothing that we make here is just our work. It is the team's work, most importantly, and the founders, the stakeholders, the shareholders, our partners from clients to suppliers, all the other business partners. Thank you so much. We stay strong here till the end of the year. It is quite of a tight year, but we have great expectations nonetheless. Once again, thank you so much, and this is where we close.